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Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by synovial 
inflammation leading to bone erosion and to systemic manifestations in patients with 
long RA duration. Although the aetiology is unknown, several observations make cur-
rently clear that CD4 T cells play a key role in the pathogenesis: (1) RA associates with 
certain polymorphisms of HLA class II molecules, and (2) the repertoire and aging of 
CD4 T cells as well as the intracellular signalling mediating CD4 T cell activation are 
altered in RA patients. We describe herein the alterations found in CD4 T cells and the 
role of these cells in the development and progression of RA.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease, which affects 0.33 to 2.65% of 
the population, showing differences between countries and studies [1–7]. It is more frequent 
in North America than Northern Europe, with Southern Europe having the lowest rate of 
incidence [8]. As other autoimmune diseases, RA is more prevalent in women than in men, 
suggesting that hormonal [9] and gender-related genetic factors [10] contribute to the devel-
opment of the disease. RA is also more frequent in the elderly, consistent with a key role of 
immune system aging in this disease [11, 12].
RA physiopathology is characterised by persistent synovial inflammation that leads to joint 
deformity, stiffness and bone erosion. Consequently, patients suffer pain and progressive dis-
ability. Although the most evident feature of RA is synovitis, extra-articular manifestations of 
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RA (ExRA) such as cardiovascular disease can be present in long-duration disease, raising the 
risk of early death [13, 14].
RA is associated to certain alleles of the major histocompatibility complex class II (MHC-II), 
and CD4 T cells of RA patients show abnormalities in intracellular signalling, repertoire and 
aging. It is then conceivable that CD4 T cells could be essential mediators in the development 
of the chronic inflammation occurring in RA. These cells are key regulators of the immune 
response secreting pro-inflammatory cytokines and cooperating with B cells for secreting 
antibodies. In fact, certain RA patients develop autoantibodies such as anti-citrullinated pro-
tein antibodies (ACPA) or rheumatoid factor (RF, which recognises the Fc portion of IgG), 
while other patients do not, indicating that RA comprises at least two different pathologies, 
seropositive and seronegative [15].
The study of CD4 T cell population has changed our understanding of RA: from the tra-
ditional paradigm, which considered that a small set of joint antigens causes the selective 
expansion of few antigen-specific cells, to a new model in which RA would be a systemic dis-
ease caused by alterations in T cell homeostasis and aging. In this chapter, we will describe the 
role of CD4 T cells in the development of RA and the abnormalities that these lymphocytes 
show in diseased individuals.
2. Aetiology of rheumatoid arthritis
Although the aetiology of RA remains elusive, genetic and environmental risk factors 
have been described [16, 17]. MHC-II genes, particularly HLA (human leukocyte antigen) 
-DRB1 alleles (the so-called shared epitope [18, 19]), constitute the strongest genetic risk fac-
tor, accounting for 50% of the genetic contribution to RA [20]. Association with HLA-DRB1 
has been established in different populations across the world [21–25], especially in ACPA-
positive pathology, and different haplotypes of HLA-DRB1 associate with distinct RA sever-
ity and treatment response [26]. Single-nucleotide polymorphisms (SNPs) in other genes have 
also been linked to RA [16], including genes coding for molecules that regulate T cell activa-
tion, which will be discussed below. These genetic associations strongly indicate a decisive 
role of helper T lymphocytes in the pathology.
The major environmental risk factor is smoking habit, which seems to alter citrullination of 
mucosal proteins [27]. Genetic and environmental risk factors work together in promoting the 
disease. For example, smoking habit alters methylation of the HLA-DRB1 region, increasing 
the chance of developing ACPA-positive RA [28, 29].
Some infectious agents might also be risk factors of RA. For example, there is a positive associ-
ation between the prevalence of periodontitis and RA [30]. Porphyromonas gingivalis, the major 
causative agent of periodontitis, produces an enzyme that induces aberrant citrullination of 
host proteins [31]. This generates neoantigens that can then be recognised by the immune 
system of the host, triggering ACPA production. In addition, it has been shown that ACPA 
from RA patients cross-react with various autoantigens and microbial and plant-citrullinated 
proteins [32]. This suggests that environmental factors such as infections and diet may trigger 
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the production of ACPA in individuals with genetic predisposition. ACPA can then cross-
react with self-proteins through molecular mimicry, inducing RA.
3. Pathophysiology of rheumatoid arthritis
A healthy joint (Figure 1A, left side) is composed of two adjacent bony ends covered with a 
layer of cartilage. The space between ends is called articular cavity, which is delimited by the 
synovial membrane on both sides and contains synovial fluid. The synovial membrane is a thin 
layer of cells, formed by two types of synoviocytes: type A or macrophage-like synovial cells 
Figure 1. Role of CD4 T cells in rheumatoid synovitis. (A) In a healthy synovial joint (left), a thin layer of synoviocytes 
delimits the joint capsule. By contrast, in RA (right), synoviocytes form an invasive synovial lining and leukocytes 
infiltrate the synovial membrane. (B) Activated CD4 T cells play a central role in inflammatory responses in the synovial 
membrane, including autoantibody production by plasma cells, secretion of inflammatory cytokines by macrophages 
and synoviocytes, bone erosion by osteoclasts and inhibition of collagen secretion by synoviocytes.
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and type B or fibroblast-like synoviocytes (FLSs). The synovial membrane produces synovial 
fluid and due to its porous organisation allows diffusion of the nutrients in serum to the avas-
cular cartilage.
The confluence of genetic susceptibility and environmental factors determines the develop-
ment of an autoimmune response that precedes clinical arthritis. For reasons poorly under-
stood, this autoimmune response exacerbates in the synovium, where leukocytes infiltrate 
causing synovial membrane inflammation (rheumatoid synovitis) (Figure 1A, right side). 
Synovial infiltrate includes both innate and adaptive immune cells [33, 34] and creates a 
microenvironment where FLSs acquire an invasive and inflammatory phenotype, leading to 
hyperplasia of the synovial lining [35, 36]. FLSs secrete matrix metalloproteinases (MMPs) 
and collagenase, promoting cartilage destruction [37]. Leukocyte infiltration and secretion of 
pro-inflammatory cytokines favour maturation of pre-osteoclasts to osteoclasts, which leads 
to bone erosion [38–40]. Cytokines and growth factors released by infiltrated cells, together 
with the hypoxia resulting from synovial hyperplasia, trigger angiogenesis [41–43], establish-
ing a feedback loop that favours continuous leukocyte infiltration and chronic inflammation.
Inflammation initiated in the synovium gives way to systemic inflammation that alters the 
function of distant tissues and organs, such as vascular endothelium, adipose tissue, liver 
and lungs. As a result, ExRA is present in RA patients, such as cardiovascular disease (CVD), 
anaemia or rheumatoid lung, among others [44].
Although different immune cells infiltrate the inflamed joint, we will focus on CD4 T cells, 
which, as mentioned above, seem to be central in the pathophysiology of RA by secreting 
cytokines and by cooperating with synovial cells.
4. Pathogenic role of CD4 T cells in rheumatoid arthritis
4.1. CD4 T cell activation and function in synovitis
CD4 T cells are the most abundant lymphocyte in the synovial infiltrate [45], where they 
regulate other cell types in the synovium and play a central role in the pathological immune 
response leading to the joint damage (Figure 1B).
4.1.1. CD4 T cell activation by DCs
Dendritic cells (DCs) are key initiators of adaptive immune responses, since they are pro-
fessional antigen-presenting cells (APCs), able to present to T cell antigenic peptides in 
the context of the MHC-II. Initially, infiltrated CD4 T cells interact with synovial DCs, 
resulting in T cell stimulation (Figure 1B). Activation of CD4 T cells requires the engage-
ment of the T cell receptor (TCR) by antigen-MHC-II complexes on the surface of the APC. 
In addition, full T cell activation requires interaction between the molecule CD28 on the 
T cell and its ligands CD80 and CD86 expressed by APCs, which provides costimulatory 
signals. Activated CD4 T cells upregulate the expression of the inhibitory molecule cyto-
toxic T lymphocyte antigen-4 (CTLA-4), which binds CD80 and CD86 with higher affinity 
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than CD28 [46]. During consecutive contacts with APCs, CTLA-4 will compete with CD28 
for CD80/CD86, and binding of CTLA-4 to these ligands will result in inhibition of T cell 
activation [47]. The importance of APC-mediated T cell costimulation for the progression 
of RA has been proved by therapy with the CTLA-4-immunoglobulin fusion protein abata-
cept. This molecule binds to CD80/CD86 on the APC, impeding binding of CD28 and, 
therefore, blocking T cell costimulation [48]. Treatment with abatacept reduces disease 
activity and radiographic progression of RA [49, 50].
4.1.2. Cooperation between CD4 T cells and B cells
B cells play a fundamental role in seropositive RA, in which patients develop autoantibodies 
contributing to inflammation and tissue damage. Autoantibodies are synthesised by plasma 
cells, which differentiate from B cells after cooperation with CD4 T cells. Upon activation, T 
cells upregulate the surface expression of CD40 ligand (CD40L or CD154), which interacts 
with CD40 expressed by B cells. During T/B cooperation, stimulation through CD40 together 
with IL-6 signalling favours isotype switching, differentiation of B cells into plasma cells and 
synthesis of antibodies such as ACPA (Figure 1B) [51]. CD4 T cells, B cells and DCs found 
in joints of RA patients range from diffuse infiltrates to follicular structures, forming ectopic 
germinal centres (EGCs) in some patients [52]. Formation of EGCs favours the formation of 
high affinity autoantibodies, increasing the severity of the disease [53]. EGCs and B cells seem 
to be critical for T cell activation in the synovium [54].
4.1.3. Regulation of FLSs by CD4 T cells
As mentioned before, FLSs are an important component of joint architecture. In a healthy joint 
(Figure 1A, left side), FLSs form the synovial lining and produce synovial fluid. FLSs acquire 
an invasive phenotype in RA, causing hyperplasia of the synovial lining (Figure 1A, right 
side). This hyperplasia originates a hypoxic environment where angiogenesis is activated, 
favouring perpetuation of inflammation. In addition, RA FLSs secrete high amounts of prote-
ases, which trigger cartilage destruction, and pro-inflammatory cytokines.
Antigen-experienced CD4 T cells affect the function of FLSs by direct cell-cell interaction. 
For example, CD4 T cells induce the production of the pro-inflammatory cytokines IL-15, 
TNF-α and IL-18 by FLSs (Figure 1B). This is dependent on CD40L-CD40 engagement as 
demonstrated by a blocking agent [55]. Collagen synthesis by FLSs is also decreased by CD4 
T cells, a process mediated, at least in part, by T cell membrane-associated IFN-γ, TNF-α and 
IL-1α [56].
4.1.4. Regulation of macrophages/monocytes by CD4 T cells
Macrophages infiltrate the RA joint, where they interact with synovial cells and produce 
the pro-inflammatory cytokine TNF-α. CD4 T cells regulate macrophages in the synovium, 
as shown by the finding that freshly isolated synovial T cells can induce the expression of 
the pro-inflammatory cytokine TNF-α by macrophages in an IL-15-dependent manner 
(Figure 1B) [57]. Resembling the behaviour of T cells in RA patients, T cells of healthy donors 
stimulated with an inflammatory cytokine cocktail can induce the production of TNF-α by 
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resting monocytes [58]. It should be noted that TNF-α production by myeloid cells is also 
induced by IL-15-stimulated NK cells [59]. Due to the central role of TNF-α in the progres-
sion of RA, as demonstrated by the succeeded neutralising therapy [60], it will be needed to 
further investigate this complex regulation of immune cells in the inflamed joint.
Monocytes are the progenitors of osteoclasts, which constitute the only cell type that is able 
to degrade bone. In health, bone resorption by osteoclasts and bone generation by osteoblasts 
are tightly regulated to maintain skeletal integrity and homeostasis. In RA, osteoclast activ-
ity in the joint is increased, resulting in an unbalanced bone erosion. Synovial CD4 T cells 
from RA patients, as well as activated peripheral blood T cells from healthy donors, express 
receptor activator of nuclear factor κB ligand (RANKL), which engages RANK expressed on 
monocytes, inducing their differentiation to osteoclasts [61, 62] and, consequently, triggering 
bone erosion (Figure 1B).
4.1.5. Role of IL-17 secretion by T cells
Synovial CD4 T cells produce pro-inflammatory cytokines themselves (Table 1). Among these, 
IL-17 expression is increased in the synovial tissue of RA patients [63], its levels correlate with 
disease activity [64] and it has a predominant role in rheumatoid pathology [65]. This cyto-
kine is produced by Th17 cells that are critical drivers of synovitis [66]. In the synovium, IL-17 
stimulates the production of pro-inflammatory cytokines by rheumatoid synovial cells [67, 68], 
triggers osteoclastogenesis [69] and impairs cartilage repair [70]. Methotrexate, a first-line con-
ventional therapeutic agent in RA, attenuates IL-17 production by peripheral blood mononu-
clear cells in vitro [71], supporting the pathogenic role of this cytokine.
Interestingly, the balance between Th17 and regulatory T cells (Treg), which exert anti-inflam-
matory functions, is shifted towards the Th17 subset in RA [72]. The first hypothesis explain-
ing the excessive Th17 response in RA is that it might be an enhanced Th17 differentiation 
due to the inflammatory environment. Th17 cells differentiate in the presence of IL-1β, IL-6 
and IL-23 [73], which are secreted by activated macrophages and dendritic cells in inflam-
matory conditions [74]. Supporting this hypothesis, both IL-23 and IL-6 levels are increased 
in patients with RA [75, 76]. IL-23 levels correlate with the activity of early arthritis [77]. A 
second hypothesis would be that intrinsic alterations in naïve CD4 T cells might prone Th17 
rather than Treg differentiation. Supporting this hypothesis, naïve RA T cells overexpress 
glucose-6-phosphate dehydrogenase (G6PD), which causes insufficient activation of ataxia 
telangiectasia mutated (ATM), leading to biased differentiation of CD4 T cells towards Th17 
and Th1 subsets (Table 2) [78].
4.2. Abnormalities in CD4 T cell activation and signalling
As mentioned in the previous sections, CD4 T cell activation in the synovium is a key event 
in RA pathology. CD4 T cell activation is initiated by interaction of the TCR with the antigen-
MHC-II expressed on the surface of an APC. Engagement of TCR/MHC-II-antigen complex 
triggers the activation of intracellular signalling networks in which phosphorylation plays 
a decisive role. The kinases Lck and ZAP70 are rapidly activated after TCR stimulation and 
activate downstream effectors such as extracellular signal-regulated kinase (ERK) to induce 
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gene expression and cell proliferation. In physiologic conditions, signalling downstream the 
TCR is tightly regulated by proteins such as phosphatases. In T cell-mediated autoimmune 
pathologies, such as RA, intracellular signalling is deregulated, leading to alterations in T cell 
responses.
Another physiological mechanism regulating T cell responses and preventing autoimmu-
nity is the elimination of self-reactive T cells. This mechanism is called tolerance and occurs 
both on immature T cells in the thymus (central tolerance) and on mature circulating T cells 
(peripheral tolerance). In RA, activation of CD4 T cells by self-antigens seems to be permitted 
by losing peripheral or central tolerance and promoted by enhanced sensitivity to self-anti-
gens due to alterations in signalling networks integrating extracellular stimuli.
Several observations indicate that peripheral blood, and not only synovial-infiltrating T cells, 
show hyper-activation in RA patients [79, 80]. An aberrant function or expression of signal-
ling molecules, some of them regulating T cell responses, has been found in CD4 T cells of RA 
patients (Table 2) and will be discussed below.
Cytokine Pathogenic role
TNF-α • Activates leukocytes, synovial fibroblasts, endothelial cells and osteoclasts
• Induces production of inflammatory cytokines
• Enhances metalloproteinase expression
• Suppresses Treg cells
IFN-γ • Increases antigen presentation
• Activates macrophages
• Increases chemokine secretion
IL-1 • Activates leukocytes, synovial fibroblasts, endothelial cells and osteoclasts
• Induces production of matrix proteinases
IL-6 • Activates leukocytes and osteoclasts
• Stimulates antibody production
IL-17 • Induces production of inflammatory cytokines
• Activates innate immune cells
• Increases osteoclastogenesis
• Stimulates neutrophil recruitment
IL-21 • Activates Th17 and B cells
Table 1. Pathogenic role of cytokines secreted by CD4 T cells in the RA synovium.
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4.2.1. PD-1
Programmed death-1 (PD-1) receptor is inducibly expressed on CD4 T cells upon activation 
through the TCR [81]. Upon binding to its ligands during TCR stimulation, PD-1 delivers 
inhibitory signals that suppress T cell activation and proliferation and impair T cell survival 
[82]. A set of SNPs in the gene coding for PD-1 are linked to RA [83–85], and PD-1 expression 
is decreased in T cells from RA patients [86]. This reduced expression would lead to a defect 
in peripheral tolerance, favouring autoimmunity.
4.2.2. LYP
The lymphoid-specific tyrosine phosphatase (LYP) is encoded by the gene PTPN22. This pro-
tein is exclusively expressed in cells of the immune system and in T cells negatively regulates 
TCR signalling by inactivating the kinases Lck and ZAP70 [87]. Therefore, LYP is an important 
inhibitor of signalling downstream the TCR. The SNP rs2476601 in PTPN22 is associated with 
RA [88, 89]. The pathological function of this SNP, which results in the LYP mutant R620W, 
remains controversial. Various reports show that the LYP R620W variant is more effective in 
Protein Alteration Consequence in CD4 T cells Reference(s)
G6PD Overexpression • Insufficient ATM activation
• Hyperproliferation
• Increased Th1/Th17 
differentiation
[78]
LYP (rs2476601 SNP) Gain of function mutation • T cell hyporesponsiveness [88–92]
TC-PTP (rs1893217(C) SNP) Reduced expression • Decreased STAT5 
phosphorylation
• Decreased FOXP3 expres-
sion upon activation
[95, 96]
CDC25B Reduced expression Not reported [99]
DUSP7 Reduced expression Not reported [99]
B-RAF
K-RAS
Overexpression • Increased ERK phosphory-
lation and signalling
• Autoreactive response to 
citrullinated peptides
[101]
PD-1 Reduced expression Not reported [91–95]
Telomerase Insufficient induction Susceptibility to apoptosis [12]
MRE11A Reduced expression • Telomeric damage
• Senescence
[11]
G6PD, glucose-6-phosphate dehydrogenase; ATM, ataxia telangiectasia mutated; LYP, lymphoid-specific tyrosine 
phosphatase; TC-PTP, T cell protein tyrosine phosphatase; STAT5, signal transducer and activator of transcription 5; 
FOXP3, forkhead box P3; CDC25B, cell division cycle 25 B; DUSP7, dual-specificity phosphatase 7; ERK, extracellular 
signal-regulated kinase; PD-1, programmed death 1; MRE11A, meiotic recombination 11 homolog A
Table 2. Alterations in gen/protein expression or activity found in CD4 T cells from RA patients and their phenotype.
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downregulating TCR signalling than the LYP WT [90, 91]. In this situation, LYP R620W would 
trigger autoimmunity because it would suppress TCR signalling of autoreactive T cells during 
negative selection in the thymus, promoting their survival and compromising central toler-
ance [92]. Molecular mechanisms leading to autoimmunity in the presence of this polymor-
phism should be further studied.
4.2.3. TC-PTP
The T cell-phosphotyrosine phosphatase (TC-PTP) is encoded by the gene PTPN2. This tyro-
sine phosphatase negatively regulates TCR and JAK-STAT signalling, being an inhibitor of T 
cell activation [93, 94]. The SNP rs1893217(C) in PTPN2 is associated with juvenile idiopathic 
arthritis and results in decreased gene expression [95]. Strikingly, decreased phosphoryla-
tion of STAT5 and reduced FOXP3 expression are found in cells carrying this mutation [96]. 
Because FOXP3 is the master regulator of Treg differentiation [97], this SNP might cause 
abnormalities in Treg functions, resulting in increased inflammation. The mechanism for this 
phenotype should be investigated.
4.2.4. CDC25B
The dual-specificity phosphatase cell division cycle 25 B (CDC25B) positively regulates cell 
proliferation by promoting G2/M transition [98]. Recently, our group has found a reduced 
expression of this phosphatase in CD4 T cells of patients diagnosed with early arthritis [99]. 
Importantly, altered CDC25B levels associate to the activity of the disease. Whether this alter-
ation causes or is a consequence of the inflammatory environment characteristic of RA, and 
its effect in T cell responses will need further investigation.
4.2.5. Regulators of ERK signalling
As mentioned before, ERK is a key effector molecule downstream TCR activation. Hence, 
defective regulation of ERK phosphorylation levels could lead to aberrant T cell responses. 
The expression of some ERK regulator is altered in T cells of RA patients.
The dual-specificity phosphatase 7 (DUSP7) negatively regulates ERK phosphorylation and 
activity [100]. Although its role in T cells has not been addressed, it is conceivable that DUSP7 
could be a negative regulator of MAPK signalling in T cells being activated. CD4 T cells of 
patients with seropositive early arthritis have reduced expression of DUSP7 [99]. The fact 
that defective expression is restricted to seropositive patients could indicate a role of this 
phosphatase in T/B cooperation. Further investigation is needed to determine the functional 
significance of DUSP7 in T cells.
The GTPase K-RAS and the kinase B-RAF are positive regulators of ERK signalling upon TCR 
stimulation. A higher TCR-induced ERK phosphorylation results in a lower T cell activation 
threshold, contributing to autoimmunity. K-RAS and B-RAF are overexpressed in T cells of 
RA patients [101]. Interestingly, overexpression of B-RAF and K-RAS increases the activation 
of CD4 T cells of healthy donors by a citrullinated vimentin peptide. This finding provides 
support to the notion that higher CD4 sensitivity could cause loss of peripheral tolerance in 
RA patients.
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4.3. Abnormalities in CD4 T cell repertoire and aging
The ability of the adaptive immune system to respond to the large diversity of pathogens 
found throughout life depends on the generation of a wide TCR repertoire. This repertoire 
is generated in the thymus, where the V, D and J segments of the TCR rearrange randomly. 
Newly generated naive T cells migrate from the thymus to the periphery to exert their func-
tions. The thymic output, however, declines throughout life. In the elderly the thymus no 
longer functions as a source of new naïve T cells, which have to be produced by replication 
of mature peripheral T cells, a process called homeostatic proliferation [102]. The expan-
sion of peripheral T cell clones generates a contraction in T cell repertoire and induces a 
phenotype of replicative stress that is characteristic of aged people [103]. Clone expansion 
of peripheral cells might favour an increased presence of autoreactive clones. Consistent 
with this idea, autoimmune signs such as autoantibody production are higher in elderly 
individuals [104].
Repertoire contraction and clonally expanded populations in the CD4 compartment have 
been reported in RA [105]. Clonal expansion was initially interpreted as a consequence of 
specific responses to synovial self-antigens, but this hypothesis is unlikely. Contraction in 
CD4 T cell diversity is not limited to the memory compartment, but involves also naïve T cells 
[106]. This seems to be due to an accelerated aging of the immune system in RA patients, in 
which the thymus function is lost earlier than in healthy people [107].
A hallmark of immune aging is the accumulation of end-differentiated effector CD4 T cells 
that lack expression of the costimulatory receptor CD28 [108]. Indeed, the frequency of CD4+ 
CD28− lymphocytes is higher in RA patients [109, 110]. These cells are producers of IFN-γ, 
display cytotoxic functions and are autoreactive [109, 111, 112]. Such phenotype could be 
mediated, at least in part, by increased expression of the NK cell-activating receptor NKG2D. 
Ligands of NKG2D are highly expressed in inflamed synovium [113].
Another hallmark of cellular aging is telomere shortening [114], and lymphocytes from RA 
patients show premature telomeric loss [115]. In naïve CD4 T cells, this is due to insufficient 
upregulation of telomerase activity (Table 2), which in addition promotes apoptosis in these 
cells [12]. Excessive loss of naive T cells will further stimulate homeostatic proliferation of 
effector T cells, providing a positive feedback loop of replicative stress.
Recently, another alteration in DNA repair machinery was found in CD4 T cells from RA 
patients [11]. The expression of repair nuclease MRE11A is decreased in these cells, leading to 
telomeric damage and upregulated senescence markers (Table 2).
4.4. CD4 T cells in extra-articular disease
Although the main site of inflammation in RA is the synovium, pro-inflammatory cytokines and 
activated cells are released to the bloodstream, leading to systemic inflammation. This inflam-
matory state has multiple ExRA on distant organs, such as skin, lungs, heart, blood or bone 
[116]. Smoking habit and autoantibodies predispose to severe ExRA [117]. Several systemic 
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pathologies are frequent in RA patients, such as systemic vasculitis, interstitial lung disease 
and pericarditis, which is the most common cardiac complication [116]. We focus here on CVD.
Chronic inflammation generates a pro-atherogenic environment in RA. Indeed, RA patients 
have increased risk of cardiovascular death [118] and higher incidence of atherosclerotic 
heart disease [119]. Atherosclerosis is an inflammatory process in which the plaque, con-
stituted by lipid accumulation on arterial walls, causes endothelial injury and activation. 
This promotes the recruitment of leukocytes, which culminates in the disruption of the 
plaque and thrombosis. Vascular inflammation in atherosclerosis and synovial inflamma-
tion in RA share features of immune activation, including accumulation of inflammatory 
macrophages and T cells, production of inflammatory cytokines and degradation of the 
extracellular matrix. High levels of soluble factors such as C-reactive protein, TNF-α and 
IL-6 are associated with coronary artery disease [120–122]. These cytokines are also elevated 
in chronic inflammation, which renders lipoproteins more atherogenic, reduces the repair 
of injured endothelium and upregulates the expression of endothelial adhesion molecules, 
which enhance leukocyte recruitment [123]. Consistent with a role of systemic inflamma-
tion in atherosclerosis, RA therapies based on methotrexate and TNF-α antagonists decrease 
CVD rates [124, 125].
As mentioned before, the CD4+CD28− T cell subset is expanded in RA [109, 110]. This T cell 
subset is also expanded in patients with unstable angina (UA) [126], a pathology in which 
the atheroma plaque is disrupted causing thrombosis. The percentage of CD4+CD28− cells 
correlates with recurrence of UA, pointing to a direct role of these cells in the progression of 
the pathology [127]. In addition, expanded CD4+ CD28− found in the atherosclerotic lesion 
includes large monoclonal populations, suggesting that these cells can recognise antigens 
in the atheroma plaque [128]. Consistently, RA patients with expansion of circulating 
CD4+CD28− cells show preclinical atherosclerotic changes, including endothelial dysfunc-
tion [129]. The implication of CD4+CD28− cells in atherosclerosis is further supported by 
anti-TNF therapy, which normalises CD28 expression [130] and decreases CVD rates [125].
5. Conclusion
RA is a chronic inflammatory disease characterised by synovitis and systemic features, such 
as exacerbated atherosclerosis. CD4 T cells are key mediators of tissue damage, both in the 
joint and in extra-articular lesions, through a variety of mechanisms. Certain alleles of the 
MHC-II as well as different alterations of signalling molecules and checkpoints for activation 
seem to favour self-antigen recognition, activation and break of tolerance. Besides, abnormali-
ties found in CD4 T cell repertoire and phenotype in patients with RA strongly suggest that in 
these patients there is an accelerated aging of the immune system that leads to oligoclonality 
and senescence of T cells, making these lymphocytes autoreactive. Understanding the mecha-
nisms underlying these systemic alterations will be essential for the development of more 
effective therapies for RA treatment.
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